Rakovina TherapeuticsRKVTF -5.71%27 EV-to-FCF is -0.93 as of Jul. 12, 2026. GuruFocus rates RKVTF with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 329 Biotechnology companies, Rakovina Therapeutics ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rakovina Therapeutics's Enterprise Value is $3.60 Mil.
Rakovina Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.86 Mil. Therefore, Rakovina Therapeutics's EV-to-FCF for today is -0.93.
The historical rank and industry rank for Rakovina Therapeutics's EV-to-FCF or its related term are showing as below:
RKVTF'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.96 Med: 0 Max: 0
Current: -0.96
RKVTF's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs RKVTF: -0.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rakovina Therapeutics's PE Ratio (TTM) for today is calculated as:
Rakovina Therapeutics's share price for today is $0.0891.
Rakovina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.306.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rakovina Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rakovina Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rakovina Therapeutics's EV-to-FCF falls into.
Rakovina Therapeutics's current Enterprise Value is $3.60 Mil.
Rakovina Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rakovina Therapeutics (RKVTF) has a EV-to-FCF of -0.93 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rakovina Therapeutics and its competitors. According to the industry distribution chart, Rakovina Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry.
Is Rakovina Therapeutics' EV-to-FCF too high?
Rakovina Therapeutics' current EV-to-FCF is -0.93. Based on the distribution chart, Rakovina Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rakovina Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rakovina Therapeutics ranks #999999 out of 329 companies for EV-to-FCF. This places Rakovina Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rakovina Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rakovina Therapeutics's current EV-to-FCF is -0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current EV-to-FCF of -0.93. The current EV-to-FCF is -0.93. Rakovina Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current EV-to-FCF is -0.93 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
27GF Score
Get the complete analysis for RKVTF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RKVTF has been successfully added to your 
